Non-surgical approach to the benign nodular goiter: New opportunities by recombinant human TSH-stimulated 131I-therapy

Endocrine

Volumn 40, Issue 3, 2011, Pages 344-353

  Bonnema, Steen Joop ^a   Fast, Søren ^a   Hegedüs, Laszlo ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Levothyroxine; Nodular goiter; Radioiodine therapy; Recombinant human thyrotropin

Indexed keywords

ANTITHYROID AGENT; GLUCOCORTICOID; IODINE 131; LEVOTHYROXINE; PLACEBO; RADIOPHARMACEUTICAL AGENT; THYROTROPIN; THYROTROPIN I 131; UNCLASSIFIED DRUG; PHARMACEUTICAL VEHICLES AND ADDITIVES; RADIOACTIVE IODINE; RECOMBINANT PROTEIN;

CONSERVATIVE TREATMENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IODINE 131 UPTAKE TEST; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NODULAR GOITER; OFF LABEL DRUG USE; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOISOTOPE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THYROID DISEASE; THYROID SWELLING; THYROIDECTOMY; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; TRACHEA COMPRESSION; RADIATION DOSE;

ADJUVANTS, PHARMACEUTIC; GOITER, NODULAR; HUMANS; IODINE RADIOISOTOPES; RADIOTHERAPY DOSAGE; RECOMBINANT PROTEINS; THYROTROPIN;

EID: 84858770501     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-011-9542-6     Document Type: Review

References (90)

1. T.H. Brix, K.O. Kyvik, L. Hegedüs, Major role of genes in the etiology of simple goiter in females: a population-based twin study. J. Clin. Endocrinol. Metab. 84, 3071-3075 (1999) (Pubitemid 30646925)
2. L. Hegedüs, S.J. Bonnema, F.N. Bennedbæk, Management of simple nodular goiter: current status and future perspectives. Endocr. Rev. 24, 102-132 (2003) (Pubitemid 36223282)
3. P. Vejbjerg, N. Knudsen, H. Perrild et al., Effect of a mandatory iodization program on thyroid gland volume based on individuals' age, gender, and preceding severity of dietary iodine deficiency: a prospective, population-based study. J. Clin. Endocrinol. Metab. 92, 1397-1401 (2007) (Pubitemid 46556416)
4. A.E. Jarløv, L. Hegedüs, T. Gjørup, J.E. Hansen, Accuracy of the clinical assessment of thyroid size. Dan. Med. Bull. 38, 87-89 (1991)
5. G.H. Tan, H. Gharib, C.C. Reading, Solitary thyroid nodule. Comparison between palpation and ultrasonography. Arch. Intern. Med. 155, 2418-2423 (1995)
6. R. Paschke, L. Hegedus, E. Alexander, R. Valcavi, E. Papini, H. Gharib, Thyroid nodule guidelines: agreement, disagreement and need for future research. Nat. Rev. Endocrinol. 7, 354-361 (2011)
7. L. Hegedüs, Clinical practice. The thyroid nodule. N. Engl. J. Med. 351, 1764-1771 (2004)
8. L. Hegedus, S.J. Bonnema, Approach to management of the patient with primary or secondary intrathoracic goiter. J. Clin. Endocrinol. Metab. 95, 5155-5162 (2010)
9. S.J. Bonnema, P.B. Andersen, D.U. Knudsen, L. Hegedüs, MR imaging of large multinodular goiters: observer agreement on volume versus observer disagreement on dimensions of the involved trachea. AJR Am. J. Roentgenol. 179, 259-266 (2002) (Pubitemid 34694847)
10. N.J. Gittoes, M.R. Miller, J. Daykin, M.C. Sheppard, J.A. Franklyn, Upper airways obstruction in 153 consecutive patients presenting with thyroid enlargement. Br. Med. J. 312, 484 (1996) (Pubitemid 26061241)
11. P.V. Pradeep, P. Tiwari, A. Mishra et al., Pulmonary function profile in patients with benign goiters without symptoms of respiratory compromise and the early effect of thyroidectomy. J. Postgrad. Med. 54, 98-101 (2008) (Pubitemid 351724191)
12. S.J. Bonnema, V.E. Nielsen, L. Hegedüs, Long-term effects of radioiodine on thyroid function, size and patient satisfaction in non-toxic diffuse goitre. Eur. J. Endocrinol. 150, 439-445 (2004) (Pubitemid 38584693)
13. F.N. Bennedbæk, H. Perrild, L. Hegedüs, Diagnosis and treatment of the solitary thyroid nodule. Results of a European survey. Clin. Endocrinol. (Oxf). 50, 357-363 (1999) (Pubitemid 29166716)
14. F.N. Bennedbæk, L. Hegedüs, Management of the solitary thyroid nodule: results of a North American survey. J. Clin. Endocrinol. Metab. 85, 2493-2498 (2000) (Pubitemid 32269206)
15. J.P. Walsh, S.A. Ryan, D. Lisewski et al., Differences between endocrinologists and endocrine surgeons in management of the solitary thyroid nodule. Clin. Endocrinol. (Oxf). 66, 844-853 (2007) (Pubitemid 47024272)
16. S.J. Bonnema, F.N. Bennedbæk, W.M. Wiersinga, L. Hegedüs, Management of the nontoxic multinodular goitre: a European questionnaire study. Clin. Endocrinol. (Oxf). 53, 5-12 (2000) (Pubitemid 30646121)
17. S.J. Bonnema, F.N. Bennedbaek, P.W. Ladenson, L. Hegedus, Management of the nontoxic multinodular goiter: a North American survey. J. Clin. Endocrinol. Metab. 87, 112-117 (2002) (Pubitemid 34084679)
18. M.C. Bhagat, S.S. Dhaliwal, S.J. Bonnema, L. Hegedüs, J.P. Walsh, Differences between endocrine surgeons and endocrinologists in the management of non-toxic multinodular goitre. Br. J. Surg. 90, 1103-1112 (2003) (Pubitemid 37152169)
19. L.A. Diehl, V. Garcia, S.J. Bonnema, L. Hegedüs, C.C. Albino, H. Graf, Management of the nontoxic multinodular goiter in Latin America: comparison with North America and Europe, an electronic survey. J. Clin. Endocrinol. Metab. 90, 117-123 (2005) (Pubitemid 40116643)
20. F.N. Bennedbæk, S. Karstrup, L. Hegedüs, Percutaneous ethanol injection therapy in the treatment of thyroid and parathyroid diseases. Eur. J. Endocrinol. 136, 240-250 (1997) (Pubitemid 27130044)
21. H. Dossing, F.N. Bennedbaek, L. Hegedus, Long-term outcome following interstitial laser photocoagulation of benign cold thyroid nodules. Eur. J. Endocrinol. 165, 123-128 (2011)
22. H. Gharib, E. Papini, R. Paschke et al., American association of clinical endocrinologists, Associazione Medici Endocrinologi, and european thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J. Endocrinol. Invest. 33, 287-291 (2010)
23. M.F. Wesche, M.M. Tiel-Van Buul, P. Lips, N.J. Smits, W.M. Wiersinga, A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J. Clin. Endocrinol. Metab. 86, 998-1005 (2001) (Pubitemid 32322972)
24. F.N. Bennedbæk, L.K. Nielsen, L. Hegedüs, Effect of percutaneous ethanol injection therapy versus suppressive doses of L-thyroxine on benign solitary solid cold thyroid nodules: a randomized trial. J. Clin. Endocrinol. Metab. 83, 830-835 (1998) (Pubitemid 28496454)
25. F. Zelmanovitz, S. Genro, J.L. Gross, Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J. Clin. Endocrinol. Metab. 83, 3881-3885 (1998) (Pubitemid 28513566)
26. Grussendorf M, Reiners C, Paschke R, Wegscheider K: Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab doi:10.1210/jc.2011-0356 (2011)
27. J.B. Stanbury, A.E. Ermans, P. Bourdoux et al., Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 8, 83-100 (1998) (Pubitemid 28082626)
28. D.P. Livadas, D.A. Koutras, A. Souvatzoglou, C. Beckers, The toxic effect of small iodine supplements in patients with autonomous thyroid nodules. Clin. Endocrinol. (Oxf). 7, 121-127 (1977) (Pubitemid 8150570)
29. A. Berghout, W.M. Wiersinga, H.A. Drexhage, N.J. Smits, J.L. Touber, Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 336, 193-197 (1990) (Pubitemid 20229056)
30. M.I. Surks, E. Ortiz, G.H. Daniels et al., Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291, 228-238 (2004) (Pubitemid 38082818)
31. J.J. Diez, P. Iglesias, An analysis of the natural course of subclinical hyperthyroidism. Am. J. Med. Sci. 337, 225-232 (2009)
32. S. Fast, S.J. Bonnema, L. Hegedus, The majority of Danish nontoxic goitre patients are ineligible for Levothyroxine suppressive therapy. Clin. Endocrinol. (Oxf). 69, 653-658 (2008)
33. R.S. Bahn, H.B. Burch, D.S. Cooper et al., Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American thyroid association and American association of clinical endocrinologists. Thyroid 21, 593-646 (2011)
34. M.A. Walter, M. Briel, M. Christ-Crain et al., Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. Br. Med. J. 334, 514 (2007)
35. S.J. Bonnema, F.N. Bennedbæk, J. Gram, A. Veje, J. Marving, L. Hegedüs, Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur. J. Endocrinol. 149, 485-492 (2003) (Pubitemid 38063062)
36. M. Dietlein, K.W. Lauterbach, H. Schicha, Treatment of toxic nodular goitres: comparative costing of radioiodine therapy and surgery. Exp. Clin. Endocrinol. Diabetes 106(Suppl 4), S66-S70 (1998) (Pubitemid 28537592)
37. L. Hegedüs, B. Nygaard, J.M. Hansen, Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? J. Clin. Endocrinol. Metab. 84, 756-760 (1999) (Pubitemid 29075717)
38. T. Watt, M. Grønvold, A.K. Rasmussen et al., Quality of life in patients with benign thyroid disorders. A review. Eur. J. Endocrinol. 154, 501-510 (2006)
39. N.N. al Suliman, N.F. Ryttov, N. Qvist, M. Blichert-Toft, H.P. Graversen, Experience in a specialist thyroid surgery unit: a demographic study, surgical complications, and outcome. Eur. J. Surg. 163, 13-20 (1997) (Pubitemid 27062346)
40. S.J. Bonnema, H. Bertelsen, J. Mortensen et al., The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J. Clin. Endocrinol. Metab. 84, 3636-3641 (1999) (Pubitemid 30645217)
41. D.A. Huysmans, A.R. Hermus, F.H. Corstens, J.O. Barentsz, P.W. Kloppenborg, Large, compressive goiters treated with radioiodine. Ann. Intern. Med. 121, 757-762 (1994)
42. R. Le Moli, M.F. Wesche, M.M. Tiel-Van Buul, W.M. Wiersinga, Determinants of longterm outcome of radioiodine therapy of sporadic non- toxic goitre. Clin. Endocrinol. (Oxf). 50, 783-789 (1999) (Pubitemid 29284513)
43. B. Nygaard, L. Hegedüs, M. Gervil, H. Hjalgrim, P. Søe-Jensen, J.M. Hansen, Radioiodine treatment of multinodular non-toxic goitre. Br. Med. J. 307, 828-832 (1993) (Pubitemid 23281746)
44. J. Bachmann, C. Kobe, S. Bor et al., Radioiodine therapy for thyroid volume reduction of large goitres. Nucl. Med. Commun. 30, 466-471 (2009)
45. S.J. Bonnema, D.U. Knudsen, H. Bertelsen et al., Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imaging. Thyroid 12, 313-317 (2002) (Pubitemid 34438935)
46. S.J. Bonnema, V.E. Nielsen, H. Boel-Jørgensen et al., Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J. Clin. Endocrinol. Metab. 92, 3424-3428 (2007) (Pubitemid 47435314)
47. V.E. Nielsen, S.J. Bonnema, H. Boel-Jørgensen, P. Grupe, L. Hegedüs, Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double- blind trial. Arch. Intern. Med. 166, 1476-1482 (2006) (Pubitemid 44125866)
48. D.A. Huysmans, W.C. Buijs, M.T. van de Ven et al., Dosimetry and risk estimates of radioiodine therapy for large, multinodular goiters. J. Nucl. Med. 37, 2072-2079 (1996) (Pubitemid 26428384)
49. M.S. Torres, L. Ramirez, P.H. Simkin, L.E. Braverman, C.H. Emerson, Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J. Clin. Endocrinol. Metab. 86, 1660-1664 (2001) (Pubitemid 32374920)
50. D.A. Huysmans, W.A. Nieuwlaat, R.J. Erdtsieck et al., Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J. Clin. Endocrinol. Metab. 85, 3592-3596 (2000)
51. V.E. Nielsen, S.J. Bonnema, H. Boel-Jørgensen, A. Veje, L. Hegedüs, Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. J. Clin. Endocrinol. Metab. 90, 79-83 (2005) (Pubitemid 40116637)
52. C.C. Albino, C.O. Mesa Jr., M. Olandoski et al., Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J. Clin. Endocrinol. Metab. 90, 2775-2780 (2005) (Pubitemid 40686323)
53. L. Braverman, R.T. Kloos, B. Law Jr., M. Kipnes, M. Dionne, J. Magner, Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr. Pract. 14, 832-839 (2008)
54. S. Fast, V.E. Nielsen, S.J. Bonnema, L. Hegedus, Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur. J. Endocrinol. 160, 517-528 (2009)
55. W.A. Nieuwlaat, A.R. Hermus, F. Sivro-Prndelj, F.H. Corstens, D.A. Huysmans, Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J. Clin. Endocrinol. Metab. 86, 5330-5336 (2001) (Pubitemid 33070255)
56. S. Fast, V.E. Nielsen, P. Grupe, S.J. Bonnema, L. Hegedus, Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J. Nucl. Med. 50, 732-737 (2009)
57. W.A. Nieuwlaat, D.A. Huysmans, H.C. Van Den Bosch et al., Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J. Clin. Endocrinol. Metab. 88, 3121-3129 (2003) (Pubitemid 36877482)
58. D.S. Duick, H.J. Baskin, Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr. Prac. 9, 204-209 (2003)
59. M.N. Silva, I.G. Rubio, R. Romao et al., Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin. Endocrinol. (Oxf). 60, 300-308 (2004) (Pubitemid 38297119)
60. O. Cohen, J. Ilany, C. Hoffman et al., Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients. Eur. J. Endocrinol. 154, 243-252 (2006)
61. M. Giusti, C. Cappi, B. Santaniello et al., Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter. Minerva Endocrinol. 31, 191-209 (2006)
62. G.J. Paz-Filho, C.O. Mesa-Junior, M. Olandoski et al., Effect of 30 mCi radioiodine on multinodular goiter previously treated with recombinant human thyroid-stimulating hormone. Braz. J. Med. Biol. Res. 40, 1661-1670 (2007)
63. E.R. Cubas, G.J. Paz-Filho, M. Olandoski et al., Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre. Int. J. Clin. Pract. 63, 583-590 (2009)
64. R. Romao, I.G. Rubio, E.K. Tomimori, R.Y. Camargo, M. Knobel, G. Medeiros-Neto, High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/ clinical hyperthyroidism. Thyroid 19, 945-951 (2009)
65. Giusti M, Caputo M, Calamia I et al.: Long-term outcome of lowactivity radioiodine administration proceeded by adjuvant recombinant human TSH pretreatment in elderly subjects with multinodular goiter. Thyroid Res. 2, 6 (2009)
66. C.C. Albino, H. Graf, G. Paz-Filho et al., Radioiodine plus recombinant human thyrotropin do not cause acute airway compression and are effective in reducing multinodular goiter. Braz. J. Med. Biol. Res. 43, 303-309 (2010)
67. S. Fast, L. Hegedus, P. Grupe et al., Recombinant human thyrotropin- stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J. Clin. Endocrinol. Metab. 95, 3719-3725 (2010)
68. C. Ceccarelli, L. Antonangeli, F. Brozzi et al., Radioiodine (131)I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine (131)I activity to be administered in patients with low uptake. Thyroid 21, 759-764 (2011)
69. M. Dietlein, B. Dederichs, C. Kobe, P. Theissen, M. Schmidt, H. Schicha, Therapy for non-toxic multinodular goiter: radioiodine therapy as attractive alternative to surgery. Nuklearmedizin 45, 21-34 (2006) (Pubitemid 44070818)
70. G. Medeiros-Neto, S. Marui, M. Knobel, An outline concerning the potential use of recombinant human thyrotropin for improving radioiodine therapy of multinodular goiter. Endocrine 33, 109-117 (2008)
71. G.J. Paz-Filho, H. Graf, Recombinant human thyrotropin in the management of thyroid disorders. Expert. Opin. Biol. Ther. 8, 1721-1732 (2008)
72. S.J. Bonnema, V.E. Nielsen, L. Hegedüs, Radioiodine therapy in non-toxic multinodular goitre. The possibility of effect-amplification with recombinant human TSH (rhTSH). Acta Oncol. 45, 1051-1058 (2006) (Pubitemid 44815502)
73. V.E. Nielsen, S.J. Bonnema, L. Hegedüs, The effects of recombinant human thyrotropin, in normal subjects and patients with goitre. Clin. Endocrinol. (Oxf). 61, 655-663 (2004) (Pubitemid 40006785)
74. S.J. Bonnema, V.E. Nielsen, H. Boel-Jorgensen et al., Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J. Clin. Endocrinol. Metab. 93, 3981-3984 (2008)
75. S.J. Bonnema, S. Fast, V.E. Nielsen et al., Serum thyroxine and age: rather than thyroid volume and serum TSH: are determinants of the thyroid radioiodine uptake in patients with nodular goiter. J. Endocrinol. Invest. 34, e52-e57 (2011)
76. W.A. Nieuwlaat, A.R. Hermus, H.A. Ross et al., Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroidstimulating hormone. J. Nucl. Med. 45, 626-633 (2004) (Pubitemid 47618593)
77. B. Nygaard, J.H. Knudsen, L. Hegedüs, A. Veje, J.E. Hansen, Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter. J. Clin. Endocrinol. Metab. 82, 2926-2930 (1997) (Pubitemid 27385650)
78. B. Nygaard, J. Faber, L. Hegedüs, Acute changes in thyroid volume and function following 131I therapy of multinodular goitre. Clin. Endocrinol. (Oxf). 41, 715-718 (1994)
79. S.J. Bonnema, Upper airway obstruction due to goiter: an overlooked problem. J. Postgrad. Med. 54, 82-83 (2008)
80. B. Nygaard, R.A. Metcalfe, J. Phipps, A.P. Weetman, L. Hegedüs, Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter. J. Endocrinol. Invest. 22, 481-485 (1999) (Pubitemid 29355567)
81. T. Angusti, A. Codegone, R. Pellerito, A. Favero, Thyroid cancer prevalence after radioiodine treatment of hyperthyroidism. J. Nucl. Med. 41, 1006-1009 (2000) (Pubitemid 30396648)
82. J.A. Franklyn, P. Maisonneuve, M. Sheppard, J. Betteridge, P. Boyle, Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353, 2111-2115 (1999) (Pubitemid 29278480)
83. J.A. Franklyn, M.C. Sheppard, P. Maisonneuve, Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 294, 71-80 (2005) (Pubitemid 41002841)
84. P. Hall, G. Berg, G. Bjelkengren et al., Cancer mortality after iodine-131 therapy for hyperthyroidism. Int. J. Cancer 50, 886-890 (1992)
85. S. Metso, A. Auvinen, H. Huhtala, J. Salmi, H. Oksala, P. Jaatinen, Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 109, 1972-1979 (2007) (Pubitemid 46744190)
86. E. Ron, M.M.Doody, D.V. Becker et al., Cancermortality following treatment for adult hyperthyroidism. Cooperative thyrotoxicosis therapy follow-up study group. JAMA 280, 347-355 (1998)
87. S. Fast, V.E. Nielsen, S.J. Bonnema, L. Hegedus, Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH. Clin. Endocrinol. (Oxf). 72, 411-416 (2010)
88. V.E. Nielsen, S.J. Bonnema, L. Hegedüs, Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J. Clin. Endocrinol. Metab. 91, 1317-1322 (2006)
89. H. Graf, S. Fast, F. Pacini et al., Modified-release recombinant human TSH (MRrhTSH) augments the effect of 131I therapy in benign multinodular goiter. Results from a multicenter international, randomized, placebo-controlled study. J. Clin. Endocrinol. Metab. 96, 1368-1376 (2011)
90. M.S. Cardia, I.G. Rubio, G. Medeiros-Neto, Prolonged follow-up of multinodular goitre patients treated with radioiodine preceded or not by human recombinant TSH. Clin. Endocrinol. (Oxf).64, 474 (2006)